34.45
1.09 (3.27%)
| Previous Close | 33.36 |
| Open | 33.72 |
| Volume | 1,257,762 |
| Avg. Volume (3M) | 1,208,957 |
| Market Cap | 2,064,109,696 |
| Price / Sales | 5.14 |
| Price / Book | 4.13 |
| 52 Weeks Range | |
| Earnings Date | 31 Jul 2025 - 4 Aug 2025 |
| Profit Margin | -54.98% |
| Operating Margin (TTM) | -44.79% |
| Diluted EPS (TTM) | -3.38 |
| Quarterly Revenue Growth (YOY) | 23.20% |
| Total Debt/Equity (MRQ) | 18.25% |
| Current Ratio (MRQ) | 4.51 |
| Operating Cash Flow (TTM) | -56.11 M |
| Levered Free Cash Flow (TTM) | -16.89 M |
| Return on Assets (TTM) | -15.04% |
| Return on Equity (TTM) | -38.22% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bearish | Bearish |
| Diagnostics & Research (Global) | Bearish | Bearish | |
| Stock | Twist Bioscience Corporation | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | 1.5 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | 2.0 |
| Average | 1.63 |
|
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Core |
| % Held by Insiders | 1.99% |
| % Held by Institutions | 114.90% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Edgepoint Investment Group Inc. | 31 Mar 2025 | 1,113,210 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 50.00 (Guggenheim, 45.14%) | Buy |
| Median | 45.00 (30.62%) | |
| Low | 33.00 (JP Morgan, -4.21%) | Sell |
| Average | 44.00 (27.72%) | |
| Total | 4 Buy, 1 Sell | |
| Avg. Price @ Call | 33.53 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Baird | 06 May 2025 | 44.00 (27.72%) | Buy | 32.75 |
| Goldman Sachs | 06 May 2025 | 48.00 (39.33%) | Buy | 32.75 |
| Guggenheim | 06 May 2025 | 50.00 (45.14%) | Buy | 32.75 |
| JP Morgan | 06 May 2025 | 33.00 (-4.21%) | Sell | 32.75 |
| Barclays | 10 Apr 2025 | 45.00 (30.62%) | Buy | 36.63 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |